Crossmark

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer

Crossref DOI link: https://doi.org/10.1038/s41523-022-00453-7

Published Online: 2022-08-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Isnaldi, Edoardo https://orcid.org/0000-0002-1055-7254
Richard, François https://orcid.org/0000-0003-4353-3619
De Schepper, Maxim

Leduc, Sophia

Maetens, Marion

Geukens, Tatjana https://orcid.org/0000-0001-8828-8739
Van Baelen, Karen https://orcid.org/0000-0002-5700-3574
Nguyen, Ha-Linh https://orcid.org/0000-0002-2538-7657
Rouas, Ghizlane

Zoppoli, Gabriele

Cardoso, Fatima https://orcid.org/0000-0002-6692-2249
Sotiriou, Christos https://orcid.org/0000-0002-5745-9977
Larsimont, Denis

Floris, Giuseppe https://orcid.org/0000-0003-2391-5425
Biganzoli, Elia https://orcid.org/0000-0003-1202-5873
Desmedt, Christine https://orcid.org/0000-0002-5223-5579
License Information

Text and Data Mining valid from 2022-08-04

Version of Record valid from 2022-08-04
More Information

Article History

Received: 1 October 2021

Accepted: 5 July 2022

First Online: 4 August 2022

Competing interests

: G.Z. declares no competing non-financial interests but the following competing financial interests: travel grants from Novartis, Pfizer, and Roche, consultation fees from Novartis, laboratory reagents from Cytiva and ThermoFisher Scientific. All remaining authors declare no competing financial or non-financial interests.

Document is current

Any future updates will be listed below